Osteoarthritis (OA)
Is complex musculoskeletal disorder with profound social and economic costs. OA is one of the top five causes of disability in the US, affecting 27-million Americans, including about 14% of adults aged 25 and older, 80% of the population over 65, and costing the Nation 1-2.5% of its gross domestic product.
27
Million
Americans
1 - 2.5%
of US gross
domesticproduct
Top 5
OA is one of
the top 5 causes of disability in the US.
Osteoarthritis (OA)
Stem cell-enriched products have been reported to promote clinical benefits
Stem cell-enriched products have been reported to promote clinical benefits in OA via anti-inflammatory and regenerative activities. However, there is no FDA-approved stem cell therapy available to patients in the US. Akan’s investigational product, StroMel™, is one of the few non-expanded native stem cell-based biological products currently in FDA-approved clinical trials in the US.